Characteristics of pulmonary complications in non-Hodgkin's lymphoma patients treated with rituximab-containing chemotherapy and impact on survival

Annals of Hematology
Kimberly KeeferAndry Van de Louw

Abstract

Patients with non-Hodgkin's lymphoma (NHL) receiving rituximab-containing chemotherapy are at risk of developing respiratory complications, but comprehensive information on these complications and their impact on survival is lacking. We performed a retrospective cohort analysis on 123 NHL patients who received rituximab-containing chemotherapy between 2009 and 2016 in order to describe the incidence, etiologies and effect on survival of respiratory complications defined by new or worsening respiratory symptoms requiring diagnostic work-up or hospitalization. Thirty patients (24%) developed respiratory complications during a follow-up time of 825 (555-1338) days after chemotherapy. They had a higher prevalence of congestive heart failure and lung or pleural involvement at diagnosis as compared to patients who did not develop complications. Overall, 58 episodes of pulmonary complications were observed after median (interquartile) times from the first and last rituximab doses of 205 (75-580) days and 27 (14-163) days respectively. Infectious etiologies accounted for 75% of the respiratory complications, followed by heart failure exacerbation, lymphomatous involvement, and ARDS. Two Pneumocystis jirovecii pneumonias were observed, ...Continue Reading

References

Aug 1, 1992·The American Review of Respiratory Disease·K Jules-ElyseeS C Gulati
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S CzuczmanC Varns
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M VoseR I Fisher
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Feb 4, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S LimatJ Y Cahn
Jun 29, 2007·American Journal of Hematology·Stephanie A WagnerDamian A Laber
Mar 4, 2008·Annals of Nuclear Medicine·Toshiki KazamaHomer A Macapinlac
Mar 15, 2008·Pharmacoepidemiology and Drug Safety·V GonzálezG Manso
Apr 15, 2008·International Journal of Hematology·Daisuke EnnishiKiyohiko Hatake
Jul 18, 2009·The European Respiratory Journal·H LiotéJ Cadranel
Dec 30, 2009·Leukemia & Lymphoma·C VulstekeP Schöffski
Dec 14, 2011·Rheumatology·Andreas V HadjinicolaouAndrew J K Ostör
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Aug 8, 2014·Leukemia & Lymphoma·Caroline AlgrinElie Azoulay
Jan 14, 2016·Leukemia & Lymphoma·Philipp WohlfarthUNKNOWN Arbeitsgruppe für hämato-onkologische Intensivmedizin der Österreichischen Gesellschaft für Internistische und Allgemeine In
Dec 24, 2017·Medical Oncology·Katarzyna Mizia-StecEdyta Płońska-Gościniak

❮ Previous
Next ❯

Methods Mentioned

BETA
bronchoalveolar lavage

Software Mentioned

SPSS
R

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.